focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Research Update on MicroRx Discovery Platform

26 Nov 2015 07:00

RNS Number : 9779G
4d Pharma PLC
26 November 2015
 

4D pharma plc

(the "Company" or "4D")

Research Update on MicroRx Discovery Platform

4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following research update on MicroRx, its proprietary platform for the discovery of novel live biotherapeutics.

Using MicroRx, 4D has to date focused on identifying innovative autoimmune, respiratory and CNS therapies. In the last 18 months the MicroRx platform has delivered a proprietary pipeline of 12 programmes and continues to be targeted at delivering more candidates across multiple disease areas. 

Over the last six months, the Company has focused part of this work in oncology and is pleased to report that it has identified an orally administered live biotherapeutic candidate that has shown efficacy in pre-clinical models of breast and lung cancers. Encouragingly, the efficacy demonstrated in these pre-clinical models is comparable to checkpoint inhibitors, a market the pharmaceutical industry expects to exceed $25bn in the next decade.

As with its other development programmes, 4D will accelerate the cancer programme further towards the clinic, aiming to have it ready for testing in patients in 12 months. We will also be targeting the MicroRx platform towards other cancers. This is another significant step for 4D, broadening both the therapeutic base and addressable markets for the therapies developed by the MicroRx platform.

Dave Norwood, Chairman, commented "We believe the work we have completed over the last six months may open the way for the development of a completely new class of cancer therapeutics. As we have demonstrated elsewhere in our pipeline, 4D is not only world leading in the discovery of novel live biotherapeutics, it also sets a new benchmark in the rapid development and clinical testing of new therapeutics. If, as we believe, we can demonstrate a favourable safety and efficacy profile, the work 4D has achieved could be a significant step forward in the treatment of cancer."

For further information please contact:

4D

+ 44 (0) 161 837 6205

Duncan Peyton, Chief Executive Officer

 

Zeus Capital Limited - Nomad and Broker

Dan Bate

+44 (0) 161 831 1512

Dominic Wilson/Phil Walker

+44 (0) 20 3829 5000

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCPGGBGGUPAGQA
Date   Source Headline
23rd Sep 20147:00 amRNSInterim results for the period ended 30 June 2014
10th Sep 201410:49 amRNSHolding(s) in Company
10th Sep 201410:45 amRNSHolding(s) in Company
2nd Sep 20147:00 amRNSResearch Update
7th Aug 20147:00 amRNSRosburix granted orphan drug designation
18th Jul 20147:00 amRNSAcquisition of The Microbiota Company Limited
15th Jul 20145:52 pmRNSHolding(s) in Company
15th Jul 20145:38 pmRNSHolding(s) in Company
11th Jul 201412:37 pmRNSResult of general meeting
10th Jul 20143:43 pmRNSHolding(s) in Company
25th Jun 20147:00 amRNSPlacing
4th Jun 20147:00 amRNSAcquisition
4th Mar 20147:04 amRNSIssue of Convertible Loan
20th Feb 20147:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.